Avrobio Inc AVRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVRO is a good fit for your portfolio.
News
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, KAMN, AVRO
-
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – SCTL, MDC, BATL, AVRO
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
-
Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CALB, AVRO, GLT, FREE
-
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BATL, AVRO, AXNX, JNPR
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AVRO, CTLT, DOOR, FANG
Trading Information
- Previous Close Price
- $1.19
- Day Range
- $1.18–1.22
- 52-Week Range
- $0.57–1.70
- Bid/Ask
- $1.20 / $1.25
- Market Cap
- $54.30 Mil
- Volume/Avg
- 204,967 / 211,849
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.avrobio.com
Valuation
|
Metric
|
AVRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVRO
|
|---|---|
Quick Ratio | 15.43 |
Current Ratio | 15.78 |
Interest Coverage | — |
Quick Ratio
AVRO
Profitability
|
Metric
|
AVRO
|
|---|---|
Return on Assets (Normalized) | −56.87% |
Return on Equity (Normalized) | −67.58% |
Return on Invested Capital (Normalized) | −64.47% |
Return on Assets
AVRO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Twlqpfrzk | Hsw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nhhdwwvj | Yxpjwz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yfpbvmq | Prkmrrm | $97.8 Bil | |
MRNA
| Moderna Inc | Tksmxrgd | Zssgr | $41.3 Bil | |
ARGX
| argenx SE ADR | Vggdlzzq | Qbcd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lmzqlfkp | Zhmq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zhqpgbtky | Dqcbxhj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qdwrmxtnc | Xzjbq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rmngpndww | Khxms | $12.5 Bil | |
INCY
| Incyte Corp | Nbxrddq | Ymnzmhs | $11.6 Bil |